CD79A and cancer: In addition to the generally consistent findings at the individual antibody level, the present study has further demonstrated that the two IgG EBV-marker combination performed as well as the four EBV-marker combination that involved both IgG and IgA markers, even more than 5 years before cancer diagnosis.